ESMO 2018 | Awaiting key results for enzalutamide and apalutamide in nmCRPC

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update of the results obtained from the Phase III trials investigating enzalutamide and apalutamide in non-metastatic castration resistant prostate cancer (nmCRPC). Dr Crabb anticipates further studies to be conducted to determine overall survival, toxicity and efficacy in these patients, and hopes that the results from further studies will guide treatment decisions made by clinicians for this subcategory of patients.